User:Mark Macbeth/Sandbox8
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | + | =''H. sapiens'' Lysine Methyltransferase, SET 7/9= | |
| - | + | ||
| - | == | + | <StructureSection load='1O9S' size='350' frame='true' side='right' caption='H. sapiens KMT 1o9s' 'scene=81/811707/Kmt_active_site/1'> |
| - | + | ||
| - | + | ||
| - | == | + | ==Introduction== |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| + | [https://en.wikipedia.org/wiki/Histone Histones] are a family of proteins that condense DNA into chromatin, and is an octamer composed of two of each protein core; H2A, H2B, H3, and H4. Histones are a globular protein, that often have N- or C-terminal tails. These tails can often be subjected to modifications by enzymes. Methylation of histones is one of the four common histone modifications. Methylation is most common on long tails of H3 and H4 due to the tail being able to enter the active site.<ref name ="DesJarlais" /> A histone can be mono-, di-, or tri- methylated. Once the histone is methylated, the DNA goes from tightly bound heterochromatin to loosely packed euchromatin. The euchromatin allows RNA pol II to bind to the DNA and start transcription. <ref name="Marino" /> Histone methylation is also a major epigenetic marker, which can be passed down from generation to generation. A epigenetic marker affects the way that genes are expressed, and can either activate or repress DNA. Histone methylation is a major epigenetic marker because it has the ability to change heterochromatin to euchromatin, and vise versa. Alterations in markers have been associated with many diseases.<ref name="Xiao" /> Lysine Methyltrasferase SET7/9 (KMT) is an enzyme that methylates the histone 3 lysine 4 (H3K4) and plays a important role in the transcription of DNA in H. sapiens.<ref name="Biterge" /> It is composed of 259 residues and is a monomer containing a SET domain. There is a two-domain architecture containing a conserved anti-parallel β-barrel and an unusual knot-like structure that creates the active site. It also contains a cofactor that plays a role in the active site.The methylation of H3K4 results in transcriptional activation.<ref name="Biterge" /> The specific methylation of H3K4 does not result in a change in charge because it is a nonpolar group being added to the lysine. A change in charge could result in tighter bound heterochromatin. | ||
| - | === SWIRM Domain === | ||
| - | The <scene name='81/811088/Swirmdomain/5'>SWIRM domain</scene> is seen in numerous enzymes that participate in histone binding and chromatin modification. The SWIRM domain of LSD-1 is 94 residues long and is comprised of an alpha-helix bundle <ref name="Stavropolous"/>. The longest helix, 𝛂C, separates the two other helix-turn-helix motifs, <scene name='81/811088/Swirmmotifs/4'>𝛂A/B and 𝛂D/E </scene><ref name="Stavropolous"/>. The SWIRM domain is associated with the oxidase domain via hydrophobic [https://en.wikipedia.org/wiki/Van_der_Waals_force van der Waals interactions] between <scene name='81/811088/Oxidaseandswirmchillin/4'>3 𝛂-helices in each domain</scene>: 𝛂A, 𝛂B, and 𝛂E motifs in the SWIRM domain and 𝛂A, 𝛂B, 𝛂M, motifs in the oxidase domain. The residues that create this hydrophobic interface (which spans nearly 1680 Ų) are practically invariant across histone-modifying proteins <ref name="Stavropolous"/>. The <scene name='81/811090/Hydrophobic_interface_new/1'> hydrophobic interface between the oxidase and SWIRM domains</scene> creates a cleft or tunnel that is also present in other chromatin modifying enzymes. This <scene name='81/811090/Hydrophobic_interface_new/3'>cleft</scene> is responsible for binding to DNA in the other enzymes through the presence of positively charged residues in the cleft <ref name="Stavropolous"/>. The SWIRM domain in LSD-1 is unique because the cleft that is formed by the hydrophobic SWIRM-oxidase interactions lacks the positively charged residues common in other enzymes <ref name="Stavropolous"/>. For this reason, it is proposed that the SWIRM cleft is used for binding of a histone tail (on the same histone as the substrate lysine) in order to hold the histone in place. Multiple experiments showed that mutations in hydrophobic residues that form the SWIRM-oxidase interface greatly reduced the catalytic activity of LSD-1 <ref name="Stavropolous"/>. This, and the proximity to the active site in the oxidase domain, exhibit the importance of the SWIRM cleft in the mechanism of LSD-1. | ||
| - | === | + | ==Structure== |
| - | + | ||
| - | ==== | + | ===SET Domain=== |
| - | + | ||
| + | The <scene name='81/811707/Overall_structure/1'>human lysine methyltransferase </scene>(HKMT) SET7/9 is 366 amino acids long. The overall structure looks like a dimer although it acts as a monomer. The structure is composed of the ΔSET7/9 domain. The ΔSET7/9 consists of the SET domain along with the pre- and post-SET regions.<ref name="Schubert" /><ref name="Yeates" /> The pre- and post-SET regions are adjacent to SET domain and are cysteine rich.<ref name="Schubert" /><ref name="Yeates" /> The pre-SET cysteine region is located near the N-terminal where the post-SET region is located near the C-terminal of the domain.<ref name="Schubert" /><ref name="Yeates" /> These regions are said to play an important role in substrate recognition and enzymatic activity.<ref name="Schubert" /><ref name="Yeates" /> | ||
| - | == | + | The SET domain is mostly defined by <scene name='81/811707/Variable_knot/2'>turns and loops</scene> with the few <scene name='81/811707/Beta_sheets/3'>antiparallel β-sheets</scene>.<ref name="Schubert" /> <scene name='81/811707/Beta-hairpin/3'>Residues 337-349</scene> form a β-hairpin that sticks out at a right angle to the surface of the enzyme.<ref name="Xiao" /> The following three residues (<scene name='81/811707/Sharp_bend/3'>350-352</scene>) accommodate a sharp bend in the peptide chain and the end of the protein adopts an <scene name='81/811707/C-term_alpha_helix/2'>α-helical conformation</scene>.<ref name="Xiao" /> The two most defining features of the SET domain are the C-terminal tyrosine and the knot-like fold. These two components have been recognized to be essential for <scene name='81/811707/Sam_isolated/2'>S-adenosyl-L-methionine</scene> (SAM) binding and catalysis.<ref name="Schubert" /> <ref name="Yeates" /> <ref name="Huang" /> The knot-like fold contains the binding sites for the cofactor SAM and the peptide substrate.<ref name="Licciardello" /> |
| - | + | ||
| - | + | [[Image:KMT_Channel.png|300 px|right|thumb|Figure 1: Narrow Lysine Channel]] | |
| + | ===Active Site and Channel=== | ||
| - | ===Inhibition by Tri-Methylated Lysine=== | ||
| - | [[Image:Tri-methylated Lysine.png|90 px|right|thumb|Figure 4: Tri-methylated lysine.]] | ||
| - | The proposed LSD-1 mechanism is supported by the fact that tri-methylated lysine substrates (Figure 4) competitively inhibit the enzyme. A substrate lysine that is tri-methylated binds to the active site but does not undergo catalysis; the inhibition is not steric (the active site is large enough to accommodate tri-methylated lysines), but is rather chemical in nature. Tri-methylated lysines do not have a free lone pair to form an aminium cation as is necessitated by the proposed mechanism, resulting in chemical inhibition of LSD-1 <ref name="Stavropolous"/>. Thus, the mechanism of LSD-1 contributes to its specificity for mono- or di-methylated lysine substrates (Figure 4). | ||
| - | = | + | The most notable feature of the HKMT is the presence of the lysine access channel as the active site. The cofactor and <scene name='81/811708/Sam_structure/3'>peptide</scene> substrate are actually located on opposite sides of the SET domain but are connected through this narrow channel (Figure 1).<ref name="Xiao" /> This channel allows these two components to interact and complete the methyltransfer. The active site in general is considerably tyrosine rich. Residues Tyr245, His297, Ser268, Tyr305, Tyr335, and Tyr337 all help to shape the <scene name='81/811707/Stick_active_site/2'>active site</scene> and the channel.<ref name="Xiao" /> The cofactor involved, SAM, provides the methyl for methylation of the lysine on its sulfur atom. |
| - | + | ||
| - | + | [[Image:Water.PNG|300 px|right|thumb|Figure 2: Water being utilized in the active site]] | |
| - | [ | + | |
| - | + | The beta hairpin stabilizes the <scene name='81/811707/Beta_hairpin_stabilizing_tyrs/1'>conformation of Tyr335 and Tyr337</scene>, while also shaping one side of the channel which the peptide binds to.<ref name="Xiao" /> The <scene name='81/811707/Peptide_binding_site/1'>peptide binding groove</scene> is composed of residues 255-268.<ref name="Xiao" /> Lysine would have trouble coming down into the active site in its charged form, but it is facilitated by the faces of the flanking tyrosines.<ref name="Xiao" /> The orientation of the lysine is such that the amine-methyl bond is aligned towards the sulfur on SAM so that it can provide the methyl. There is an important water in the active site (Figure 2) as well that acts as a stabilizer for lysine, and helps to shift the lone pair on the nitrogen towards the sulfur of SAM. <ref name="Xiao" /> | |
| - | + | ||
| + | |||
| + | == Function == | ||
| + | |||
| + | [[Image:KMT Mechanism .png|500 px|right|thumb|Figure 3: Histone Methylation by HKMT Mechanism]] | ||
| + | |||
| + | The N from the lysine serves as a nucleophile that attacks the electrophilic CH<sub>3</sub> that is present in the AdoMet. The sulfur that the CH<sub>3</sub> is attached to pulls the electrons towards itself to weaken the bond between the sulfur and the carbon. This weak bond allows for the N to break that bond and take the methyl group. The N on the lysine is being stabilized by Tyr residues and a water molecule (Figure 3). This allows the N to gain the methyl and take up that positive charge. | ||
| + | |||
| + | The conserved regions of KMT has been found to be vital for function. Multiple studies have found that a mutation to any of the conserved tyrosine residues continues to monomethylate SAM, while it also creates di-methylation and tri- methylation of SAM.<ref name="Del Rizzo" /> In a recent study, Y245A and Y305F were created through site-directed mutagenesis.<ref name="Del Rizzo" /> Due to size, Ala245 was found to create a larger opening of the channel than tyrosine, which allowed for further methylation of SAM. <ref name="Del Rizzo" /> However, Y305F also showed the same characteristics of di- and tri-methylation, most likely due to a decrease of tyrosine residue interaction with water.<ref name="Del Rizzo" /> As there are four invariant conserved tyrosine residues (Tyr305, Tyr245, Tyr335, Tyr337) in the active site, this finding indicates that the function of KMT is dependent on the presence of tyrosine residues in the active site. <ref name="Del Rizzo" /> | ||
| + | |||
| + | == Relevance == | ||
| + | |||
| + | ===Renal Fibrosis=== | ||
| + | [[Image:Sam_vs_sinefungin.png|400 px|right|thumb|Figure 4: Structural differences between SAM and Sinefungin]] | ||
| + | The inhibition of KMT SET 7/9 has been found to enhance renal fibrosis.<ref name="Sun" /> H3K4 methylation activates the transcription of fibrotic genes, and the suppression of the H3K4 methylation was found to enhance renal fibrosis in a mouse model.<ref name="Sun" /> Sinefungin, a competitive methyltransferase inhibitor, binds to KMT to inhibit SAM.<ref name="Sun" /> SAM and Sinefungin have similar structures (Figure 4), differing only with the removal of a sulfide and the replacement of a methyl to an amine. The amine replaces the methyl donor for the reaction of KMT, inhibiting the reaction and preventing methylation. Without the methylation of H3K4, the transcription of fibrotic genes is deactivated, leading to renal fibrosis.<ref name="Sun" /> | ||
| + | |||
| + | ===Cancer=== | ||
| + | |||
| + | Many studies have shown that lysine methyltransferases lead to the inhibition of cancers, therefore they are being studied as possible cancer therapy treatments. Lysine methylation contributes to the inactivation of a tumor suppressor gene. Due to this, KMTs are being studied as possible biomarkers for the detection of cancers. Inhibitors of KMT, such as Sinefungin (Figure 4), were used in a study to observe KMT’s effect on cancerous cells. It was found that when KMT is deregulated, tumor behavior increases due to a lack of methylation, indicating the importance of the histone methylation. <ref name=Xuejiao /> | ||
| + | |||
| + | </StructureSection> | ||
== References == | == References == | ||
| + | <ref name="Xiao">PMID: 12540855 </ref> | ||
| + | <ref name ="Licciardello" <ref>DOI: 10.1016/C2014-0-02189-2</ref> | ||
| + | <ref name="Schubert">PMID: 12826405 </ref> | ||
| + | <ref name="Yeates">PMID: 12372294 </ref> | ||
| + | <ref name="Huang">PMID: 9632640 </ref> | ||
| + | <ref name="Del Rizzo">PMID: 20675860 </ref> | ||
| + | <ref name="Sun">PMID: 20930066 </ref> | ||
| + | <ref name="Xuejiao" <ref> DOI: 10.2174/1568009611313050007 </ref> | ||
| + | <ref name="DesJarlais" <ref> DOI: 10.1021/acs.biochem.5b01210 </ref> | ||
| + | <ref name="Marino">PMID: 16209651 </ref> | ||
| + | <ref name="Biterge" <ref> DOI: 10.15406/mojcsr.2016.03.00047</ref> | ||
<references/> | <references/> | ||
| - | + | ==Student Contributors== | |
| + | Ashley Crotteau | ||
| + | |||
| + | Parker Hiday | ||
| - | + | Lauren Allman | |
| - | + | ||
| - | + | ||
| - | + | ||
Revision as of 13:24, 16 April 2019
H. sapiens Lysine Methyltransferase, SET 7/9
| |||||||||||
References
[3] [8] [5] [6] [7] [9] [10] [11] [1] [2] [4]
- ↑ 1.0 1.1 DesJarlais R, Tummino PJ. Role of Histone-Modifying Enzymes and Their Complexes in Regulation of Chromatin Biology. Biochemistry. 2016 Mar 22;55(11):1584-99. doi: 10.1021/acs.biochem.5b01210. Epub , 2016 Jan 26. PMID:26745824 doi:http://dx.doi.org/10.1021/acs.biochem.5b01210
- ↑ 2.0 2.1 Marino-Ramirez L, Kann MG, Shoemaker BA, Landsman D. Histone structure and nucleosome stability. Expert Rev Proteomics. 2005 Oct;2(5):719-29. PMID:16209651 doi:http://dx.doi.org/10.1586/14789450.2.5.719
- ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 3.9 Xiao B, Jing C, Wilson JR, Walker PA, Vasisht N, Kelly G, Howell S, Taylor IA, Blackburn GM, Gamblin SJ. Structure and catalytic mechanism of the human histone methyltransferase SET7/9. Nature. 2003 Feb 6;421(6923):652-6. Epub 2003 Jan 22. PMID:12540855 doi:10.1038/nature01378
- ↑ 4.0 4.1 4.2 doi: https://dx.doi.org/10.15406/mojcsr.2016.03.00047
- ↑ 5.0 5.1 5.2 5.3 5.4 5.5 5.6 Schubert HL, Blumenthal RM, Cheng X. Many paths to methyltransfer: a chronicle of convergence. Trends Biochem Sci. 2003 Jun;28(6):329-35. PMID:12826405
- ↑ 6.0 6.1 6.2 6.3 6.4 6.5 Yeates TO. Structures of SET domain proteins: protein lysine methyltransferases make their mark. Cell. 2002 Oct 4;111(1):5-7. PMID:12372294
- ↑ 7.0 7.1 Huang S, Shao G, Liu L. The PR domain of the Rb-binding zinc finger protein RIZ1 is a protein binding interface and is related to the SET domain functioning in chromatin-mediated gene expression. J Biol Chem. 1998 Jun 26;273(26):15933-9. PMID:9632640
- ↑ 8.0 8.1 doi: https://dx.doi.org/10.1016/C2014-0-02189-2
- ↑ 9.0 9.1 9.2 9.3 9.4 9.5 Del Rizzo PA, Couture JF, Dirk LM, Strunk BS, Roiko MS, Brunzelle JS, Houtz RL, Trievel RC. SET7/9 catalytic mutants reveal the role of active site water molecules in lysine multiple methylation. J Biol Chem. 2010 Oct 8;285(41):31849-58. Epub 2010 Aug 1. PMID:20675860 doi:http://dx.doi.org/10.1074/jbc.M110.114587
- ↑ 10.0 10.1 10.2 10.3 10.4 Sun G, Reddy MA, Yuan H, Lanting L, Kato M, Natarajan R. Epigenetic histone methylation modulates fibrotic gene expression. J Am Soc Nephrol. 2010 Dec;21(12):2069-80. doi: 10.1681/ASN.2010060633. Epub 2010, Oct 7. PMID:20930066 doi:http://dx.doi.org/10.1681/ASN.2010060633
- ↑ 11.0 11.1 Tian X, Zhang S, Liu HM, Zhang YB, Blair CA, Mercola D, Sassone-Corsi P, Zi X. Histone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and prevention. Curr Cancer Drug Targets. 2013 Jun;13(5):558-79. doi:, 10.2174/1568009611313050007. PMID:23713993 doi:http://dx.doi.org/10.2174/1568009611313050007
Student Contributors
Ashley Crotteau
Parker Hiday
Lauren Allman
